Nebulized Interferon a Breakthrough if Results Reproducible
Updated: Jul 22
A clinical trial of 101 patients using an interferon-like nebulizer treatment produced a 79% lower risk of patients developing severe disease compared to those given a placebo.
Preliminary findings of a double-blind, placebo-controlled trial studying 101 patients from nine specialist hospital sites in the U.K. between March 30 and May 27 present possibly the best results so far for the treatment of Covid-19.
The trial utilized a treatment of SNG001, a naturally occurring form of the antiviral protein interferon beta, which was administered directly into the lungs via a nebulizer.
The treatment produced a 79% reduced likelihood of developing severe disease and patients "were more than twice as likely to recover (defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’) over the course of the treatment period compared to those receiving placebo" according to the study authors."
Additionally, the study found that breathlessness was “markedly reduced” in patients who received the drug compared to those in the control arm.
It was noted that three subjects (6%) died after being randomised to placebo, but there were no deaths among those given the treatment.
The clinical trial was conducted by the Southampton, UK-based pharmaceutical company Synairgen and the results of the trial are awaiting peer-review.